Vaccine – Medical Alley Association


Children with Mild COVID-19 May Not Develop Antibodies; Oral Vaccine Booster Shows Promise in Monkey Study

Oct 20 (Reuters) – The following is a summary of some recent studies on COVID-19. They include research that warrants further study to corroborate the findings and that have yet to be certified by peer review. Children with mild COVID-19 may lack antibodies afterward Children who contract a mild case of COVID-19 may not develop […]

The Future of Vaccines With Cynthia Biffert, Vice President of GMP Nucleic Acids at Aldevron

Cynthia (Cindy) Biffert started her career with Aldevron in 2002 in upstream manufacturing, helping establish the company’s QC department as QC Manager, assisting in the creation of Aldevron’s proprietary GMP-Source® quality system, and in deploying the GMP service lines as a Director of Biomanufacturing. As Senior Director of Biomanufacturing, she helped launch neoGMP®, a service level […]

The Future of Vaccines With Aaron Fisk, General Manager of Microbiologics Virology Division

Aaron Fisk has been with Microbiologics since 2015. Prior to Microbiologics, Aaron led the Human Resources efforts at Automotive Parts Headquarters, a regional automotive parts wholesale and retail business, for over ten years. Aaron is a licensed attorney in the state of Minnesota. He received an undergraduate degree from University of Wisconsin-La Crosse, a Juris […]

At The Table – State: February 25, 2021

MAA Day at the Capitol  It’s already here – 2021 Virtual Medical Alley Day at the Capitol! Plans are nearly finalized for our day at the state Capitol, so be sure to register for this members-only opportunity by Monday, March 1!   While this year’s events will look a bit different, our team is looking forward to connecting […]

At The Table – State: January 28, 2021

Opening Weeks of Session  While 2021 began rather eventfully, there was some semblance of tradition and normalcy during the start of this new legislative term. New members were sworn in (albeit virtually), committees began meeting, and bills were introduced. January has been mostly an orientation month: opportunities for legislators to hear overview presentations from various departments across the state with little official business.   COVID-19 has […]

At The Table – December 18, 2020

Governor Walz’ Latest Executive Order  During a press conference on December 18, Governor Tim Walz updated COVID-19 restrictions through Executive Order 20-103. Key points include:   Elementary School Reopening  On January 18, 2020, all Minnesota elementary schools will be allowed to operate in-person classes, so long as they have the appropriate strategies and safety measures in place.  Social Gatherings and Fitness Centers  Starting […]

Do Your Health Benefits Actually Benefit?

We’ve all seen the reports. Health care costs are expected to rise again. Mercer predicts an increase of 4.4% in 2021, but notes that we must keep in mind the many unknowns facing employer plan sponsors next year, such as COVID-related costs (potentially including vaccines) and delayed or cancelled care. It’s time to control what […]

Nucleus Networks Initiates First-in-Human Trial of Symvivo’s Oral COVID-19 Vaccine Candidate, bacTRL-Spike™

Brisbane, Australia  October 19, 2020 – Nucleus Networks announced today that Symvivo Corporation has received regulatory approval to initiate a Phase 1, first-in-human trial of bacTRL-Spike™, an orally-delivered, room temperature stable DNA vaccine candidate for the prevention of COVID-19.   Symvivo has partnered with Nucleus Network, Australia’s largest Phase 1 clinical trials specialist, to initiate a Phase 1 trial evaluating […]

Nucleus Network Begins Clinical Trial of COVID-19 Antibody Treatment

Melbourne, Australia, Friday, 11th September. Australia’s largest Phase 1 clinical trials specialist, Nucleus Network, has this week started the first human trials of a potential COVID-19 treatment developed by Singlomics (Beijing DanXu) Biopharmaceuticals and licensed by BeiGene, Ltd. Twenty-four healthy participants, aged 18 to 59 years of age, have been screened to take part this […]

Nucleus Network commences Novavax’ Phase 1/2 COVID-19 vaccine trial in Australia

Melbourne, Australia, Tuesday 26th May, Australia’s largest Phase 1 Clinical trials specialist, Nucleus Network, has today commenced dosing the first human participants for the Phase 1/2 trial of NVX‑CoV2373, a SARS-CoV-2 Recombinant Spike Protein Nanoparticle vaccine, at its Melbourne clinic. Nucleus Network has begun the Phase 1/2 COVID-19 vaccine trial in Australia on behalf of […]

Keep your finger on the pulse of Medical Alley from anywhere with the ALLEY NEWSLETTER